Scantox is pleased to announce our participation as sponsor at the Novel CNS Biomarker Summit 2026, taking place in London.
As the development of innovative therapies for neurological and neurodegenerative diseases continues to accelerate, the identification and validation of reliable CNS biomarkers have become critical for advancing drug discovery and clinical development. This summit brings together leading experts from across the pharmaceutical, biotechnology, and research communities to discuss the latest advances, challenges, and opportunities in CNS biomarker science.
At Scantox, we are committed to supporting the development of safer and more effective therapies through our integrated nonclinical and translational research services. During the event, our team will showcase how our expertise in neuroscience, biomarker development, bioanalysis, and preclinical safety assessment helps clients generate high-quality data and make informed development decisions.
We look forward to connecting with industry colleagues, sharing insights, and exploring new collaborations that will help drive innovation in CNS drug development. Visit our booth to learn how Scantox can support your next neuroscience program.
We look forward to seeing you in London!
